PriceTargets.com logo

Mineralys Therapeutics - MLYS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.50
  • Forecasted Upside: 191.81%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.48 As of 04/26/2024 12:08 PM ET
▲ +0.44 (3.99%)

This chart shows the closing price for MLYS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mineralys Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MLYS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MLYS

Analyst Price Target is $33.50
▲ +191.81% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Mineralys Therapeutics in the last 3 months. The average price target is $33.50, with a high forecast of $37.00 and a low forecast of $30.00. The average price target represents a 191.81% upside from the last price of $11.48.

This chart shows the closing price for MLYS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Mineralys Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2024The Goldman Sachs GroupInitiated CoverageBuy$30.00Low
3/26/2024Lifesci CapitalReiterated RatingOutperformLow
8/8/2023Credit Suisse GroupLower TargetOutperform ➝ Outperform$38.00 ➝ $37.00Low
3/16/2023Credit Suisse GroupLower TargetOutperform$40.00 ➝ $38.00Low
3/7/2023Evercore ISIInitiated CoverageOutperformLow
3/7/2023Wells Fargo & CompanyInitiated CoverageOverweight$27.00Low
3/7/2023Credit Suisse GroupInitiated CoverageOutperform$40.00Low
3/7/2023GuggenheimInitiated CoverageBuy$32.00Low
3/7/2023Bank of AmericaInitiated CoverageBuy$39.00Low
3/7/2023Stifel NicolausInitiated CoverageBuy$45.00Low
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Mineralys Therapeutics logo
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Read More

Today's Range

Now: $11.48
Low: $11.17
High: $11.48

50 Day Range

MA: $13.38
Low: $10.75
High: $16.15

52 Week Range

Now: $11.48
Low: $5.85
High: $17.70

Volume

6,386 shs

Average Volume

154,888 shs

Market Capitalization

$569.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Mineralys Therapeutics?

The following sell-side analysts have issued reports on Mineralys Therapeutics in the last twelve months: Credit Suisse Group AG, Lifesci Capital, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for MLYS.

What is the current price target for Mineralys Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Mineralys Therapeutics in the last year. Their average twelve-month price target is $33.50, suggesting a possible upside of 191.8%. Credit Suisse Group AG has the highest price target set, predicting MLYS will reach $37.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $30.00 for Mineralys Therapeutics in the next year.
View the latest price targets for MLYS.

What is the current consensus analyst rating for Mineralys Therapeutics?

Mineralys Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MLYS will outperform the market and that investors should add to their positions of Mineralys Therapeutics.
View the latest ratings for MLYS.

What other companies compete with Mineralys Therapeutics?

Other companies that are similar to Mineralys Therapeutics include Verve Therapeutics, Olema Pharmaceuticals, CureVac, Nuvation Bio and Phibro Animal Health. Learn More about companies similar to Mineralys Therapeutics.

How do I contact Mineralys Therapeutics' investor relations team?

The company's listed phone number is 888-378-6240 and its investor relations email address is [email protected]. The official website for Mineralys Therapeutics is www.mineralystx.com. Learn More about contacing Mineralys Therapeutics investor relations.